Leukemia, B-Cell
Showing 26 - 50 of >10,000
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 10, 2023
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Tampa (Fludarabine, Cyclophosphamide,
Recruiting
- Chronic Lymphocytic Leukemia
- +4 more
- Fludarabine
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Jan 12, 2023
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- +6 more
- (no location specified)
Apr 12, 2023
B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (U-CAR-T Cells (LstCAR019))
Withdrawn
- B-cell Acute Lymphoblastic Leukemia
- B-ALL
- U-CAR-T Cells (LstCAR019)
-
Kunming, Yunnan, ChinaKunming Hope of Health Hospital
Nov 27, 2022
B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (UCAR-T Cells)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- B-ALL
- UCAR-T Cells
-
Kunming, Yunnan, China920th Hospital of Joint Logistics Support Force of People's Libe
Dec 7, 2022
Lymphoproliferative Disorders, Premalignant, Monoclonal B-Cell Lymphocytosis Trial (No intervention)
Not yet recruiting
- Lymphoproliferative Disorders
- +3 more
- No intervention
- (no location specified)
Jan 30, 2023
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Cyclophosphamide injection
- +2 more
-
Charleston, South CarolinaHollings Cancer Center at Medical University of South Carolina
Jan 18, 2023
B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma Trial in Pittsburgh (Chimeric Antigen Receptor
Recruiting
- B-Cell Lymphoma
- +8 more
- Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
-
Pittsburgh, PennsylvaniaAHN Cancer Institute - West Penn Hospital
Aug 10, 2022
B-cell Acute Lymphoblastic Leukemia Trial (single dose of CNCT19)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- single dose of CNCT19
- (no location specified)
Dec 19, 2022
Leukemia, B-Cell Trial in Houston (Autologous TriCAR T-cells and lymphodepletion chemo)
Not yet recruiting
- Leukemia, B-Cell
- Autologous TriCAR T-cells and lymphodepletion chemotherapy
-
Houston, Texas
- +1 more
Nov 3, 2021
B Cell Leukemias, B Cell Lymphomas Trial in Philadelphia (CART22 cells transduced with a lentiviral vector to express anti-CD22
Recruiting
- B Cell Leukemias
- B Cell Lymphomas
- CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jan 19, 2022
B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)
Not yet recruiting
- B Precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
- (no location specified)
Sep 25, 2023
Patients Who Received Inotuzumab Ozogamicin for B-cell ALL That
Not yet recruiting
- Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
- Inotuzumab Ozogamicin
- (no location specified)
Nov 3, 2022
CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)
Recruiting
- CLL
- +9 more
- TG-1801
- Ublituximab
-
Fayetteville, Arkansas
- +4 more
Jan 20, 2023
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +15 more
- Anti-CD19/CD20/CD22 CAR T-Cells
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 4, 2022
Lymphoblastic Leukemia Trial in Palo Alto (Dasatinib)
Not yet recruiting
- Lymphoblastic Leukemia
-
Palo Alto, CaliforniaStanford University
Aug 14, 2023
CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL Trial in Suzhou (Treatment)
Recruiting
- CAR
- +2 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 27, 2022
Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplasia Trial (Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi))
Not yet recruiting
- Leukemia
- +12 more
- Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
- (no location specified)
Mar 20, 2023
Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (allogenic CD19-CAR-NK cells)
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- allogenic CD19-CAR-NK cells
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 11, 2023
Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (Anti-CD19
Recruiting
- Lymphoblastic Leukemia
- +5 more
- Anti-CD19 CAR T-cells
-
Singapore, Singapore
- +1 more
Dec 4, 2022
B Cell Leukemia Trial in Seattle (Autologous CD19 CAR+ EGFTt + T cells)
Active, not recruiting
- B Cell Leukemia
- Autologous CD19 CAR+ EGFTt + T cells
-
Seattle, WashingtonSeattle Children's Hospital
Feb 15, 2022
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia Trial in Beijing
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- chimeric antigen receptor T cell
-
Beijing, Beijing, ChinaBeijing Boren Hospital
Aug 12, 2022
Venetoclax Tablets Crushed and Dissolved Into a Solution
Not yet recruiting
- Hematologic Malignancy
- +18 more
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Nov 8, 2023
ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory Trial (Tafasitamab)
Not yet recruiting
- ALL, Childhood B-Cell
- +2 more
- Tafasitamab
- (no location specified)
Nov 25, 2022